Anyone had targeted treatment for KRAS G12R, MDM2 and SMAD4 Y412?

Posted by angeleji2 @angeleji2, Dec 9 11:31am

I received Genomic Findings report from Foundation Medicine, has anyone had targeted treatment for KRAS G12R, MDM2 amplification and SMAD4 Y412? I meet with my Oncologist to review the result this coming Friday but wanted to get more insights from you all so I can take in some knowledge to ask more intelligent questions. Thank you!!

Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.

Yes. I am on a clinical trial that includes a combination of drugs. One targets KRAS G12D specifically and the other is “panKRAS” targeting the KRAS family of mutations.
If you have not tried one of the standards of care therapies yet; your doctor can use this information to match you to the one that has the most success shrinking tumors with your particular gene characteristics.
So glad you are at a facility that recommended this. It is very important on this healing journey.

REPLY

Of the somatic mutations reported, the KRAS G12R variant is targetable. The following link indicates the three trials that are open for reciting participants. Click each link for the specifics of the trial, eligibility/exclusion criteria and the sites where it is being conducted.
.
https://clinicaltrials.gov/search?cond=Pancreatic%20Cancer&intr=KRAS%20G12R

REPLY

There are two additional immunotherapy (vaccine) trials sponsored by Elicio Pharmaceutical. ELI-002-2P covers the KRAS G12D and G12R variants. ELI-002-7P (AMPLIFY) trial,is a pan-KRAS trial covering G12D, G12R and five other KRAS variants. More information on the trials can be obtained by calling PanCAN.org at 877.272.6226, M-F, 7:00am-5:00pm PT. A case manager can provide details on sites recruiting, contact details, eligibility/exclusion criteria.

REPLY
@stageivsurvivor

There are two additional immunotherapy (vaccine) trials sponsored by Elicio Pharmaceutical. ELI-002-2P covers the KRAS G12D and G12R variants. ELI-002-7P (AMPLIFY) trial,is a pan-KRAS trial covering G12D, G12R and five other KRAS variants. More information on the trials can be obtained by calling PanCAN.org at 877.272.6226, M-F, 7:00am-5:00pm PT. A case manager can provide details on sites recruiting, contact details, eligibility/exclusion criteria.

Jump to this post

Thanks so much for the information. This is very helpful!

REPLY
@gamaryanne

Yes. I am on a clinical trial that includes a combination of drugs. One targets KRAS G12D specifically and the other is “panKRAS” targeting the KRAS family of mutations.
If you have not tried one of the standards of care therapies yet; your doctor can use this information to match you to the one that has the most success shrinking tumors with your particular gene characteristics.
So glad you are at a facility that recommended this. It is very important on this healing journey.

Jump to this post

Thanks so much!! Since I've had the whipple surgery, the current plan is to power-wash the micrometasis. I hope there's no tumors to shrink. It's helpful to know about panKRAS. I will do more research on this!! THANK YOU.

REPLY
@angeleji2

Thanks so much!! Since I've had the whipple surgery, the current plan is to power-wash the micrometasis. I hope there's no tumors to shrink. It's helpful to know about panKRAS. I will do more research on this!! THANK YOU.

Jump to this post

"the current plan is to power-wash the micrometasis." Could you please explain this procedure, ma'am?

REPLY
Please sign in or register to post a reply.